REDOX and Anti Oxidants

Boyd Mudenda MD

Redox and Antioxidants

Basic definitions and biologic importance

1) What is Redox?

Redox = reduction–oxidation



Oxidation = loss of electrons

Reduction = gain of electrons

OIL RIG

Oxidation Is Loss; Reduction Is Gain of electrons

In biology, redox reactions are essential for:


Energy production


Cell signaling


Immune defense


Detoxification


Control of oxidative stress

2) What is an Antioxidant?

An antioxidant is a molecule or system that helps neutralize, regulate, or limit damage from oxidants / free radicals.

Antioxidants help maintain redox balance by preventing excessive oxidative damage to:


DNA


Proteins


Lipids / cell membranes


Mitochondria


Tissues

Examples


Vitamin C


Vitamin E


Carotenoids


Polyphenols


Glutathione


Catalase


Superoxide dismutase


Selenium-dependent antioxidant enzymes

Key message | Redox is the electron-transfer balance system; antioxidants help keep that system from tipping into harmful oxidative stress.

What Antioxidants Do

Antioxidants help neutralize or regulate free radicals and reactive oxygen / nitrogen species (ROS/RNS).

The goal is **redox balance**: enough oxidant activity for useful biologic functions, but not so much that chronic oxidative damage occurs.

Normal / physiologic oxidant levels

Normal levels of oxidants are beneficial and necessary for health.

- Cell signaling
- Host defense
- Adaptation to stress

What antioxidants do

Help neutralize or regulate free radicals and ROS/RNS to preserve redox homeostasis.

Excess oxidants / oxidative stress

Excess oxidants can damage important biomolecules and tissues.

- DNA
- Proteins
- Lipids
- Mitochondria
- Tissues

Common dietary antioxidants / antioxidant systems



- Vitamin C
- Vitamin E
- Carotenoids
- Polyphenols
- Flavonoids
- Selenium-containing antioxidant enzymes

Main health roles

Cell protection

Helps limit oxidative injury to DNA, membranes, and proteins

Immune function

Supports normal immune-cell activity and inflammatory control

Vascular health

Helps reduce oxidative stress that can impair endothelial function

Detoxification systems

Supports glutathione, catalase, superoxide dismutase, and NRF2-regulated enzymes

Healthy aging biology

May reduce cumulative oxidative stress, though aging is not driven by oxidation alone

Key message: Antioxidants support healthy living by preserving redox balance and protecting cells when present in the right amount.

Role of Antioxidants in Healthy Living

Antioxidants maintain redox balance

Enough oxidant activity for normal signaling and immune defense, but not so much that it causes chronic oxidative damage.

What antioxidants do

Help neutralize or regulate free radicals and reactive oxygen/nitrogen species (ROS/RNS).

Physiologic / normal oxidant levels

Oxidants in normal amounts are beneficial.

- Cell signaling
- Host defense
- Adaptation to stress

Excess oxidants / chronic oxidative stress

Excess oxidants can cause chronic oxidative damage.

- DNA damage
- Protein damage
- Lipid damage
- Mitochondrial injury
- Tissue damage

Common antioxidants / antioxidant systems

- Vitamin C
- Vitamin E
- Carotenoids
- Polyphenols
- Flavonoids
- Selenium-dependent antioxidant enzymes (Se)

Main health roles

1. **Cell protection** — Helps limit oxidative injury to DNA, membranes, and proteins
2. **Immune function** — Supports normal immune-cell activity and inflammatory control
3. **Vascular health** — Helps reduce oxidative stress that can impair endothelial function
4. **Detoxification systems** — Supports glutathione, catalase, superoxide dismutase, and NRF2-regulated enzymes (GSH, CAT, SOD)
5. **Healthy aging biology** — May reduce cumulative oxidative stress, though aging is not driven by oxidation alone

Key message: Antioxidants support healthy living by preserving redox homeostasis and protecting cells when present in the right balance.

Best Source of Antioxidants: Food, Not Megadoses

Strong practical advice: get antioxidants from whole foods

Colorful plant-rich diets are preferred over high-dose isolated antioxidant pills.

Whole-food antioxidant sources


Berries


Citrus fruits


Leafy greens


Cruciferous vegetables


Tomatoes


Carrots


Legumes


Nuts


Seeds


Whole grains


Tea


Coffee


Herbs & spices (e.g., turmeric, garlic, rosemary, cinnamon)


Olive oil (extra virgin)

Foods deliver antioxidants together with fiber, minerals, vitamins, and thousands of interacting phytochemicals.

1. Antioxidants
Fiber
Vitamins & minerals
Phytochemical synergy

Antioxidant-rich foods often also provide fiber, low saturated fat, and useful vitamins and minerals.

Why food patterns are different

- Multiple nutrients together
- Better overall diet quality
- Natural food matrix and interactions

High-dose isolated antioxidant supplements are different

Large randomized trials have generally not shown strong protection from single antioxidant supplements against cancer, cardiovascular disease, or other chronic diseases.

Examples with limited support as broad chronic-disease preventives

- Vitamin C
- Vitamin E
- Beta-carotene
- Other single antioxidants

Single-nutrient megadoses are not the same as whole-food dietary patterns.

Key message: Favor food-based antioxidant patterns rather than assuming high-dose single supplements will prevent chronic disease.

Core Concept: Redox Reactions in Cells



Redox reactions = electron-transfer reactions

In cells, redox reactions mainly involve ROS and RNS

ROS (Reactive Oxygen Species)

Superoxide ($O_2^{\bullet -}$)



Hydrogen peroxide (H_2O_2)

Hydroxyl radical ($^{\bullet}OH$)

RNS (Reactive Nitrogen Species)

Nitric oxide (NO)

Peroxynitrite ($ONOO^-$)

Controlled / physiological levels

Not simply toxic waste

Cell signaling

Redox signaling

Homeostasis

Adaptive cellular responses

The same ROS/RNS molecules can lead to either beneficial signaling or harmful damage depending on concentration and duration.

High or chronic levels

DNA damage

Protein damage

Lipid peroxidation

Mitochondrial injury

Stromal tissue damage

ROS/RNS are double-edged molecules:
signaling at controlled levels, damaging during persistent oxidative stress.

Redox Biology in Prevention, Therapy, and AML Differentiation

Redox biology is context-dependent: protective in prevention, exploitable in therapy, and mechanistically important in AML differentiation.

1. Cancer prevention

Redox balance is protective

A) Physiologic redox balance

DNA protection | Cellular homeostasis | Controlled signaling | Tissue protection

B) Chronic oxidative stress

DNA damage | Lipid peroxidation | Inflammatory signaling | Carcinogenesis

Blanket antioxidant supplementation can be ineffective or harmful.

Whole-food balance is different from indiscriminate supplements.

2. Cancer therapy

Controlled redox overload can be therapeutic

A) Many malignant cells already live near a high-ROS state

1) Increase ROS further

ROS

2) Weaken antioxidant defenses

Glutathione (GSH) | Thioredoxin (Trx) | NRF2 | Mitochondrial metabolism

Outcomes

Apoptosis | Ferroptosis (Fe^{2+}) | Mitochondrial collapse | DNA damage | Proteotoxic stress

Antioxidants are not always universally beneficial during therapy; context matters.

3. AML differentiation

Redox signaling can drive myeloid maturation

A) Differentiation block in AML

Immature blast / promyelocyte

B) Differentiation therapy restores maturation

Blast / promyelocyte → Mature myeloid cell

C) APL paradigm

ATRA + ATO + PML–RARA

ATRA + arsenic trioxide (ATO) promotes differentiation and antileukemic activity.

D) How redox fits

1. Controlled ROS promotes maturation signaling

Transcription factors | MAPK | Mitochondria

2. ATO is targeted and redox-active

- PML–RARA degradation
- PML nuclear body restoration
- Differentiation + apoptosis

3. Leukemic stem cells often maintain low ROS

- Quiescence
- ROS-removing capacity
- Potential vulnerability

4. Excess ROS can drive resistance

ROS

- Subtype dependence
- NRF2 / antioxidant defenses
- Mitochondrial state
- Risk of genomic instability / resistance

Broader AML redox targeting is promising but must account for subtype and resistance biology.

Key message: In prevention, balance protects. In therapy, redox overload can kill cancer cells.
In AML differentiation, redox signaling supports maturation but requires subtype-specific, resistance-aware targeting.

Role of Redox Biology in Cancer Prevention

















Important Prevention Implications of Redox Biology

Prevention goal: support physiologic redox balance

Not indiscriminate elimination of oxidants

Natural antioxidant-rich dietary patterns

fruits, vegetables, polyphenols, fiber, micronutrients

Whole-food patterns support physiologic defenses

- Normal redox balance
- Detoxification support
- Immune function
- Anti-inflammatory tone

High-dose isolated antioxidant supplements

Different from whole-food patterns

1. **ATBC:** beta-carotene increased lung cancer risk in smokers.
2. **CARET:** beta-carotene supplementation increased lung cancer risk in smokers / asbestos-exposed populations; active group had 28% higher lung cancer incidence.
3. **SELECT:** selenium or vitamin E did not prevent prostate cancer; later analyses linked vitamin E to increased prostate cancer risk.

High-dose isolated supplements may be harmful in some settings

NRF2 / KEAP1 signaling: central but double-edged

Protective in normal tissue

NRF2 activation

↓

antioxidant and detoxification enzymes

↓

protection from carcinogens

Potential tumor advantage

Persistent NRF2 activation in established tumors

↓

ROS

survival under oxidative stress, chemotherapy, radiotherapy, and metabolic pressure

Key message: favor food-based antioxidant patterns, avoid indiscriminate high-dose antioxidant pills, and remember redox biology is context-dependent.

In cancer, redox biology is biphasic

Increasing ROS

1 Low / moderate ROS


Normal signaling


Immune defense


Differentiation


Apoptosis signaling

2 Chronic elevated ROS


DNA damage


Genomic instability


Inflammation


Mutagenesis


Tumor initiation

3 Very high ROS beyond antioxidant capacity


Cancer-cell death

Ferroptosis


Apoptosis


Loss of leukemic stem-cell fitness

Physiologic & protective
Supports normal cell function and host defense

→

Tumor-promoting zone
Sustained ROS drives malignancy

→

Cytotoxic & lethal
Excess ROS overwhelms defenses and triggers cell death

Redox biology in cancer is biphasic: Moderate ROS **supports** normal physiology; chronic elevation **promotes** tumor initiation and progression; very high ROS exceeds antioxidant capacity and **drives** cancer-cell death pathways.

Acute Myeloid Leukemia (AML) and Differentiation

AML is characterized by a block in myeloid differentiation.
Differentiation therapy aims to restore maturation rather than simply kill blasts.

1. Core differentiation concept

AML



Immature blasts / promyelocytes

Block in myeloid differentiation

Accumulation of immature blasts

Differentiation therapy

Blast / promyelocyte

Mature myeloid cell

Restore maturation

Promote differentiation rather than only cytotoxic killing

APL: classic success

ATRA + arsenic trioxide (ATO)
Targets the PML–RARA fusion
Converts acute promyelocytic leukemia (APL) into one of the most curable leukemias

ATRA and ATO are the classic differentiating agents in APL; broader AML differentiation therapy is more complex and subtype-dependent.

1. Controlled ROS can promote maturation



Moderate oxidative signaling can support myeloid maturation.

Controlled ROS may help push leukemic promyelocytes or blasts toward differentiation.

2. Arsenic trioxide (ATO) is targeted and redox-active



ATO also generates oxidative stress and mitochondrial injury as part of its antileukemic effect.

Redox biology is double-edged: beneficial when controlled, harmful when excessive or misdirected.

3. Leukemic stem cells (LSCs) often maintain low ROS

AML LSCs may be quiescent, mitochondrially regulated, and protected by antioxidant systems.

Redox disruption may help eliminate relapse-driving cells.

4. Excess ROS can also drive resistance



ROS is not always beneficial in AML.

FLT3-ITD AML → NADPH oxidase–mediated oxidative signaling → Drug resistance / genomic instability

Excess or dysregulated ROS can promote resistance biology.

Key message: AML differentiation therapy focuses on restoring maturation. In APL, ATRA + ATO is the paradigm. Redox signaling can promote differentiation, contribute to ATO activity, expose leukemic stem-cell vulnerabilities, and also drive resistance when excessive.

Role of Redox Biology in Cancer Therapy

In established cancer, redox manipulation can work in two opposite ways.

Therapeutic context determines whether redox control protects normal tissue or drives cancer-cell death.

A. Protect normal cells

Reduce treatment-related toxicity in normal tissues

- Limit chemotherapy injury
- Limit radiotherapy injury
- Protect normal tissues
- Support treatment tolerability

Challenge

Avoid protecting tumor cells.

Redox therapy is double-edged:

benefit depends on dose, timing, cellular context, and tumor biology.

B. Push cancer cells over the oxidative threshold

Exploit the high-ROS state of many cancer cells

Many cancer cells already live near a high-ROS state.

1. **Increase ROS further**

2. **Weaken antioxidant defenses**
   - Glutathione (GSH)
   - Thioredoxin (Trx)
   - NRF2
   - Mitochondrial metabolism
   - Cystine uptake

- Apoptosis
- Ferroptosis
- Mitochondrial collapse
- DNA damage
- Proteotoxic stress

Clinical implication

The idea that “antioxidants are good” is too simplistic. During chemotherapy, radiotherapy, targeted therapy, or differentiation therapy, antioxidants may theoretically interfere with ROS-dependent treatment mechanisms unless there is a clear indication.

Key message: In cancer therapy, redox manipulation can either protect normal tissue or selectively kill cancer cells by pushing them beyond their oxidative limit.

Biological and Genetic Basis of Acute Promyelocytic Leukemia (APL / APML)

APL is a biologically distinct subtype of AML in which malignant cells are arrested at the promyelocyte stage of myeloid differentiation.

Normal myeloid maturation



Normal differentiation proceeds

Central genetic event



t(15;17)(q24;q21)

↓

PML::RARA fusion gene

↓

PML–RARA fusion protein

Translocation joins the PML gene on chromosome 15 to the RARA gene on chromosome 17.

Effect in APL



PML–RARA oncoprotein blocks retinoic-acid–driven myeloid maturation and causes accumulation of abnormal promyelocytes.

How the fusion protein causes disease



What is unique about APL?

- Biologically distinct AML subtype
- Arrest at promyelocyte stage
- Driven by **PML–RARA** fusion oncoprotein

Key biologic consequence

- RA — Failure of normal retinoic-acid signaling
- Impaired myeloid maturation
- Expansion of abnormal promyelocytes

Key message: APL is defined by t(15;17), which creates the *PML::RARA* fusion gene. The resulting PML–RARA oncoprotein blocks retinoic-acid–driven differentiation, arresting cells at the promyelocyte stage and leading to accumulation of abnormal promyelocytes.

Normal Retinoic Acid Signaling vs PML–RARA Fusion in APL

APL arises from a differentiation block: normal retinoic-acid–driven myeloid maturation is replaced by persistent transcriptional repression caused by the PML–RARA fusion protein.

1. Normal biology: retinoic acid drives myeloid maturation

1. **Retinoic acid (RA) ligand**



2. **RARA receptor activation in the nucleus**

RARA is a nuclear receptor. Depending on ligand binding and corepressor / coactivator complexes, it can repress or activate transcription.

3. **Transcription of maturation genes**

Granulocytic differentiation genes **ON**

4. **Cell maturation**



Promyelocyte → Mature granulocyte (neutrophil)

Retinoic acid → RARA activation → transcription of maturation genes → promyelocytes mature into granulocytes / neutrophils

Normal hematopoiesis | Differentiation proceeds | Maturation restored

2. Genetic lesion: PML–RARA fusion

1. **PML–RARA fusion protein**
Abnormal transcriptional regulator

2. **Binds to retinoic-acid response elements (RAREs)**

3. **Recruitment of corepressor complex**



Persistent corepressor recruitment / excessive transcriptional repression

4. **Differentiation genes OFF**



Differentiation genes OFF
Retinoic-acid response elements repressed

5. **Blocked cell maturation**



Promyelocyte → Accumulation of abnormal promyelocytes

PML–RARA fusion → excessive transcriptional repression → blocked granulocytic differentiation → accumulation of abnormal promyelocytes

APL lesion | Differentiation block | Abnormal promyelocyte accumulation

Core concept

The fundamental biologic basis of APL is a differentiation block rather than simply uncontrolled proliferation alone.

Normal pathway

- RA activates RARA
- Differentiation genes expressed
- Promyelocytes mature

VS.

APL pathway

- PML–RARA represses transcription
- Differentiation genes silenced
- Promyelocytes accumulate

Key message: In normal myelopoiesis, retinoic acid signaling through RARA drives granulocytic maturation. In APL, the PML–RARA fusion protein enforces transcriptional repression, blocking differenttation and causing accumulation of abnormal promyelocytes.

PML Disruption, Coagulopathy, Cooperating Lesions, and Therapeutic Implications in APL

APL is driven by the PML–RARA fusion, which causes a dual biologic defect, severe coagulopathy, and distinctive sensitivity to differentiation therapy.

3. Role of PML disruption

Normal PML



- apoptosis
- senescence
- DNA-damage response
- genomic stability

Normal PML organizes PML nuclear bodies and supports tumor-suppressive functions.

PML–RARA disruption



- Impaired tumor-suppressive nuclear organization
- Reduced apoptosis
- Defective genomic-stress responses

Dual biologic problem in APL

RARA signaling	Blocks retinoic-acid–dependent myeloid differentiation
PML nuclear body biology	Impairs tumor-suppressive nuclear organization, apoptosis, and genomic-stress responses

Why ATRA and ATO are complementary

- ATRA → RARA / transcriptional differentiation side
- arsenic trioxide (ATO) → PML / degradation / nuclear-body side

4. Coagulopathy: why APL is a medical emergency



Suspected APL = emergency

Start **ATRA** promptly, often before complete genetic confirmation.

5. Additional mutations and cooperating lesions



These lesions contribute to disease biology but do not replace PML–RARA as the central driver.

6. Therapeutic implication

Therapy	Main biological target	Main effect
ATRA	RARA portion of PML–RARA	Restores retinoid-responsive transcription and differentiation
Arsenic trioxide (ATO)	PML portion of PML–RARA	Promotes PML–RARA degradation, restores PML nuclear bodies, induces apoptosis
ATRA + ATO	Both sides of APL biology	Differentiation, oncoprotein degradation, leukemia eradication

APL is the paradigm of oncoprotein-targeted differentiation therapy.

Bottom line

APL is caused primarily by the PML–RARA fusion gene, usually from t(15;17). This fusion protein blocks granulocytic differentiation, disrupts PML nuclear bodies, promotes accumulation of abnormal promyelocytes, and contributes to severe coagulopathy. The same biology makes APL uniquely sensitive to ATRA plus arsenic trioxide, which reverse the differentiation block and degrade the disease-driving oncoprotein.

Role of ATRA in APL / APML Differentiation

In acute promyelocytic leukemia (APL / APML), ATRA — all-*trans* retinoic acid (tretinoin) — is the classic differentiation-inducing agent.
ATRA is the differentiation-unlocking drug in APL.

1 APL disease mechanism



Immature promyelocytes / blasts

PML–RARA fusion protein

- PML–RARA oncoprotein blocks promyelocytes at an immature stage
- Interferes with normal retinoic-acid receptor signaling
- Prevents myeloid differentiation →

2 Main role of ATRA



- ATRA binds the RARA portion of PML–RARA
- Releases the transcriptional block on genes required for granulocytic maturation
- Promotes differentiation rather than directly killing blasts

3 Simplified mechanistic sequence

1. ATRA binds RARA component of PML–RARA



2. Changes corepressor / coregulator binding



3. Restores retinoic-acid–responsive transcription



4. Releases the differentiation block

5. Leukemic promyelocytes mature into granulocytes / neutrophil-like cells



4 Biologic effect of ATRA



- Forces malignant promyelocytes to mature
- Converts proliferating immature leukemic cells into differentiated cells with limited lifespan
- Restores maturation signaling and granulocytic differentiation
- ATRA does not mainly work by directly killing blasts

5 How ATRA complements arsenic trioxide (ATO)

Agent	Main target/action in APL	Main biologic effect
ATRA	Targets the RARA / transcriptional differentiation side of PML–RARA	Restores maturation signaling and induces differentiation
Arsenic trioxide (ATO)	Targets the PML / degradation / nuclear body side of PML–RARA	Promotes PML–RARA degradation, restores PML nuclear bodies, contributes to apoptosis

Together, ATRA + ATO attack complementary parts of APL biology and have transformed APL into a highly curable leukemia subtype.

Clinical significance

- Start ATRA promptly when APL is suspected
- Rapidly begins to reverse the differentiation block
- Helps reduce life-threatening coagulopathy
- ATRA alone is usually insufficient for durable cure
- Commonly combined with ATO and/or chemotherapy depending on risk category and protocol

Bottom line: ATRA binds the RARA portion of PML–RARA, restores retinoid-driven transcription, releases the promyelocyte maturation block, and drives leukemic promyelocytes toward mature granulocytic differentiation.

Arsenic Trioxide (ATO) in APML / APL Differentiation

In acute promyelocytic leukemia (APML / APL), arsenic trioxide (ATO) is a central targeted differentiation and leukemia-eradicating agent.

ATO is not merely a cytotoxic poison; it is a fusion-protein–directed therapy.

APML disease block



PML–RARA fusion protein blocks promyelocytes from maturing into normal myeloid cells.

Result: accumulation of leukemic promyeelocytes.

Normal goal of differentiation therapy



Restore maturation rather than simply kill blasts.

ATO target

PML–RARA fusion protein

ATO targets the **PML** portion of PML–RARA.

Main mechanistic sequence

1. ATO binds PML–RARA



2. Promotes SUMOylation / ubiquitination



3. Proteasomal degradation of PML–RARA



4. Restoration of PML nuclear bodies

5. Release of the differentiation block

6. Differentiation of leukemic promyelocytes



7. Apoptosis / leukemia eradication



Biologic consequences

Restores PML nuclear body function

Removes the maturation arrest

Promotes myeloid differentiation

Contributes to apoptosis of leukemic cells

ATO acts as both a differentiation-inducing and leukemia-eradicating agent.

Why ATO is special in APL

- Fusion-protein–directed therapy
- Targets the oncoprotein driving the disease
- Not just nonspecific cytotoxicity
- Central to differentiation-based cure of APL

Key message: In APL, ATO binds the PML moiety of PML–RARA, drives oncoprotein degradation, restores PML nuclear bodies, releases the differentiation block, and leads to differentiation plus apoptosis of leukemic promyelocytes.

How ATO Complements ATRA in APML / APL Differentiation

ATRA and arsenic trioxide (ATO) attack complementary sides of the PML–RARA fusion protein, driving differentiation and leukemia eradication.

ATO
ATO mainly acts through the PML side



PML–RARA fusion protein

ATRA
ATRA mainly acts through the RARA side

ATRA: differentiation through the RARA pathway



Main effect: restores maturation signaling and differentiation.

ATRA + ATO together attack both sides of the fusion protein

ATO: targeted and redox-active



Redox-related role



Pro-oxidant activity contributes to antileukemic effect when leukemic cells are pushed beyond oxidative tolerance.

Why the combination is highly effective

ATRA restores retinoid-driven transcription and maturation



ATO restores PML biology, degrades PML–RARA, and adds redox-mediated apoptosis

Together they transformed APML / APL from highly fatal to one of the most curable AML subtypes

Practical summary

	Function of ATO in APML	Result
1	Targets PML component of PML–RARA	Direct oncoprotein-directed therapy
2	Promotes PML–RARA degradation	Removes differentiation block
3	Restores PML nuclear bodies	Re-establishes normal nuclear organization and tumor-suppressive signaling
4	Generates oxidative / mitochondrial stress	Promotes apoptosis of leukemic promyelocytes
5	Combines with ATRA	Produces powerful differentiation plus leukemia-eradicating effect

Bottom line: In APML, arsenic trioxide promotes differentiation by degrading the PML–RARA fusion protein and restoring PML nuclear body function; it also adds redox-mediated mitochondrial stress and apoptosis. Its partnership with ATRA is the classic model of successful differentiation therapy in leukemia.

Therapeutic interpretation for AML

In AML, oxidants may have three distinct roles

1 Differentiation signal



Help overcome maturation arrest

2 Cytotoxic stress



Push blasts or leukemia stem cells (LSCs) beyond redox tolerance

3 Resistance / adaptation signal

Promote survival pathways, DNA damage, clonal evolution, or drug resistance

Redox-directed AML therapy must be calibrated — not merely pro-oxidant or antioxidant.

APL paradigm: ATRA + ATO

ATRA

Promotes transcriptional differentiation

+

ATO (arsenic trioxide)

Promotes PML–RARA degradation, oxidative stress, apoptosis, and eradication of leukemia-initiating activity

Non-APL AML





Results are more heterogeneous

Bottom line

Cancer prevention: redox balance is protective; chronic oxidative stress promotes carcinogenesis; blanket antioxidant supplementation may be ineffective or harmful.

Cancer therapy: malignant cells can be vulnerable to redox overload, so controlled induction of oxidative stress can be therapeutic.

AML differentiation: redox signaling can drive myeloid maturation, especially in APL treated with ATRA plus arsenic trioxide. In broader AML, targeting must account for subtype, leukemic stem-cell biology, mitochondrial state, NRF2 / antioxidant defenses, and risk of resistance.

Redox Biology in Prevention, Therapy, and AML Differentiation

Redox biology is context-dependent: protective in prevention, exploitable in therapy, and mechanistically important in AML differentiation.

1. Cancer prevention

Redox balance is protective

A) Physiologic redox balance

DNA protection | Cellular homeostasis | Controlled signaling | Tissue protection

B) Chronic oxidative stress

DNA damage | Lipid peroxidation | Inflammatory signaling | Carcinogenesis

Blanket antioxidant supplementation can be ineffective or harmful.

Whole-food balance is different from indiscriminate supplements.

2. Cancer therapy

Controlled redox overload can be therapeutic

A) Many malignant cells already live near a high-ROS state

1) Increase ROS further

ROS

2) Weaken antioxidant defenses

Glutathione (GSH) | Thioredoxin (Trx) | NRF2 | Mitochondrial metabolism

Outcomes

Apoptosis | Ferroptosis (Fe^{2+}) | Mitochondrial collapse | DNA damage | Proteotoxic stress

Antioxidants are not always universally beneficial during therapy; context matters.

3. AML differentiation

Redox signaling can drive myeloid maturation

A) Differentiation block in AML

Immature blast / promyelocyte

B) Differentiation therapy restores maturation

Blast / promyelocyte → Mature myeloid cell

C) APL paradigm

ATRA + ATO + PML–RARA

ATRA + arsenic trioxide (ATO) promotes differentiation and antileukemic activity.

D) How redox fits

1. Controlled ROS promotes maturation signaling

Transcription factors | MAPK | Mitochondria

2. ATO is targeted and redox-active

- PML–RARA degradation
- PML nuclear body restoration
- Differentiation + apoptosis

3. Leukemic stem cells often maintain low ROS

- Quiescence
- ROS-removing capacity
- Potential vulnerability

4. Excess ROS can drive resistance

ROS

- Subtype dependence
- NRF2 / antioxidant defenses
- Mitochondrial state
- Risk of genomic instability / resistance

Broader AML redox targeting is promising but must account for subtype and resistance biology.

Key message: In prevention, balance protects. In therapy, redox overload can kill cancer cells.
In AML differentiation, redox signaling supports maturation but requires subtype-specific, resistance-aware targeting.